表位特异性抗肿瘤免疫抑制甲状腺乳头状癌的肿瘤播散
研究纳入150例甲状腺乳头状癌(PTC)患者、40例桥本甲状腺炎(HT)患者、21例健康对照及27239例健康白人,分析HLA I类限制性甲状腺过氧化物酶(TPO)和甲状腺球蛋白(Tg)表位特异性T细胞与临床结局的关系。PTC患者TPO和Tg特异性CD8+ T细胞频率较健康对照大幅升高(均P < 0.005),与HT患者相似;HLA-DQB1*03阳性PTC患者远处转移风险显著降低(RR 0.170,95%CI 0.037至0.755,P < 0.05),而HLA-DRB1*03阳性和HLA-DQB1*02阳性患者风险显著升高(HLA-DRB1*03:RR 4.400,95%CI 1.378至14.05,P < 0.05;HLA-DQB1*02:RR 3.692,95%CI 1.102至12.38,P < 0.05)。结论:PTC患者存在肿瘤表位特异性免疫,HLA-DQB1*03对转移播散具有保护作用。
要点
- PTC患者TPO和Tg特异性CD8+ T细胞频率较健康对照大幅升高,与HT患者相似。
- HLA-DQB1*03阳性PTC患者远处转移风险显著降低(RR 0.170,95%CI 0.037至0.755)。
- HLA-DRB1*03和HLA-DQB1*02阳性PTC患者远处转移风险显著升高(RR分别为4.400和3.692)。
核心结论
- PTC患者存在肿瘤表位特异性免疫,HLA-DQB1*03对转移播散具有保护作用,结果对新免疫检查点抑制剂治疗选择有直接意义。
研究设计与样本
- 纳入150例PTC患者、40例HT患者、21例健康对照及27239例健康白人(用于HLA分型)。
- 采用HLA I类限制性TPO和Tg表位特异性T细胞四聚体分析,分析HLA II类表型、T细胞免疫与临床病程的相关性。
主要发现
- PTC患者TPO和Tg特异性CD8+ T细胞频率较健康对照大幅升高(TPO P < 0.005,Tg P < 0.005),与HT患者相似。
- HLA-DQB1*03阳性PTC患者远处转移风险显著低于其他单倍型患者(RR 0.170,95%CI 0.037至0.755,P < 0.05)。
- HLA-DRB1*03阳性PTC患者远处转移风险显著高于其他单倍型患者(RR 4.400,95%CI 1.378至14.05,P < 0.05)。
- HLA-DQB1*02阳性PTC患者远处转移风险显著高于其他单倍型患者(RR 3.692,95%CI 1.102至12.38,P < 0.05)。
- HLA-DQB1*03阳性PTC患者体外对肿瘤表位反应性增强,其淋巴结转移灶中亦发现肿瘤表位特异性CD8+ T细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Papillary thyroid cancer (PTC) is characterized by a lymphocytic infiltration. PTC patients with lymphocytic infiltration may have a better clinical outcome. OBJECTIVE: Characterization of tumor epitope-specific immunity and correlation analyses with the clinical outcome. PATIENTS: 150 PTC patients; 40 Hashimoto thyroiditis (HT) patients; 21 healthy controls; 27,239 healthy whites (for HLA typing). MAIN OUTCOME MEASURES: HLA class I restricted thyroperoxidase (TPO) and thyroglobulin (Tg) epitope-specific T cells (tetramer analyses), correlation analyses between HLA class II phenotypes, T cell immunity, and the clinical course. RESULTS: The frequency of TPO- and Tg-specific CD8+ T cells in PTC patients was largely increased compared with healthy controls (TPO and Tg, P < 0.005 and P < 0.005) and was similar to those in HT patients. HLA-DQB1*03-positive PTC patients had a significantly lower risk [risk ratio (RR), 0.170; 95% confidence interval (CI), 0.037 to 0.755; P < 0.05] and HLA-DRB1*03-positive and HLA-DQB1*02-positive PTC patients a significantly higher risk (HLA-DRB1*03: RR, 4.400; 95% CI, 1.378 to 14.05; P < 0.05; HLA-DQB1*02: RR, 3.692; 95% CI, 1.102 to 12.38; P < 0.05) for distant metastases, compared with patients with other haplotypes. HLA-DQB1*03-positive PTC patients revealed an increased responsiveness of tumor epitopes in vitro. These tumor epitope-specific CD8+ T cells were also found in lymph node metastases of HLA-DQB1*03-positive PTC patients. CONCLUSION: We demonstrate a tumor epitope-specific immunity in PTC patients and the protective role of HLA-DQB1*03 against metastatic spread. These results have direct implications for new treatment options with immune checkpoint inhibitors.
引用
- Ehlers M, Kuebart A, Hautzel H, et al. Epitope-Specific Antitumor Immunity Suppresses Tumor Spread in Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2017. PMID: 27860539. doi:10.1210/jc.2016-2469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。